Most drugs are metabolized by CYP3A enzymes, and variations in expression levels of these enzymes are believed to determine whether patients will have a positive or adverse drug response. Little is known about the mechanisms that underlie inter-individual differences in CYP3A expression, but the mapping of human genome sequence variations will facilitate the search for answers.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RETRACTED ARTICLE: ABCB1 (1199G>A) polymorphism regulates the efficacy of docetaxel and imatinib mesylate in HEK293 recombinant cell lines
Cancer Chemotherapy and Pharmacology Open Access 21 June 2015
-
Cunninghamella as a Microbiological Model for Metabolism of Histamine H3 Receptor Antagonist 1-[3-(4-tert-Butylphenoxy)propyl]piperidine
Applied Biochemistry and Biotechnology Open Access 16 September 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ames, B. N. et al. Nature's chemicals and synthetic chemicals: comparative toxicology. Proc. Natl. Acad. Sci. U.S.A. 87, 7782–7786 (1990).
Rendic, S. & Di Carlo, F. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413–580 (1997).
Nelson, D. R. et al. Cytochrome P450 and the individuality of species. Arch. Biochem. Biophys. 369, 1–10 (1999).
Shimada, T. et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414–423 (1994).
Wrighton, S. A. & Thummel, K. E. CYP3A in Metabolic Drug Interactions (eds. Levy, R. H., Thummel, K. E., Trager, W. F., Hansten, P. D. & Eichelbaum, M.) 115–133 (Lippincott Williams & Wilkins, Philadelphia, 2000).
Özdemir, V. et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373–388 (2000).
Domanski, T. L. et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol . 59, 386–392 (2001).
Sata, F. et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48–56 (2000).
Westlind, A. et al. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream region. Biochem. Biophys. Res. Commun. 259, 201–205 (1999).
Moore, J. T. & Kliewer, S. A. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153, 1–10 (2000).
Xie, W. et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406, 435–439 (2000).
Xie, W. et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 14, 3014–3023 (2000).
The International SNP Map Working Group A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928–933 (2001).
Goodwin, B. et al. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329–1339 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eichelbaum, M., Burk, O. CYP3A genetics in drug metabolism. Nat Med 7, 285–287 (2001). https://doi.org/10.1038/85417
Issue Date:
DOI: https://doi.org/10.1038/85417
This article is cited by
-
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Nature Reviews Drug Discovery (2017)
-
Differenzialindikation von Opioiden in der Schmerztherapie
Der Anaesthesist (2017)
-
RETRACTED ARTICLE: ABCB1 (1199G>A) polymorphism regulates the efficacy of docetaxel and imatinib mesylate in HEK293 recombinant cell lines
Cancer Chemotherapy and Pharmacology (2015)
-
CYP3A5 polymorphism, amlodipine and hypertension
Journal of Human Hypertension (2014)
-
Drug interactions result from a number of underlying pharmacokinetic and pharmacodynamic mechanisms
Drugs & Therapy Perspectives (2013)